In this study, we found no evidence of a difference in take rate between patients who achieved a pCR (chemotherapy-sensitive disease) and those with residual disease (chemotherapy resistance) in either TN or HER2+ breast cancers. This evidence concerns the gene ERBB2 and breast cancer.